Chinese Biotech Influence Poses Emerging Risk for U.S.-Based Companies
U.S. biotech companies are increasingly relying on innovations developed in China, raising concerns about risk and uncertainty for investors. Jefferies estimates that nearly a third of the industry's licensing spending by 2025 is directed toward Chinese-origin drugs, particularly in antibody-drug conjugates (ADCs), where Chinese firms now supply close to 90% of global activity.
Tickers: $SMMT
Topics: China's role in drug development global biotech licensing U.S. biotech investment risks